1.30Open1.30Pre Close0 Volume12 Open Interest5.00Strike Price0.00Turnover156.07%IV9.09%PremiumDec 20, 2024Expiry Date0.93Intrinsic Value100Multiplier27DDays to Expiry0.37Extrinsic Value100Contract SizeAmericanOptions Type-0.6064Delta0.2245Gamma3.13Leverage Ratio-0.0121Theta-0.0024Rho-1.90Eff Leverage0.0042Vega
Geron Stock Discussion
Almost low enough
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
No comment yet